LIPID PROFILE AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH AUTOIMMUNE HYPOTHYROIDISM
- 1Department of Endocrinology, ”Nicolae Testemitanu” State University of Medicine and Pharmacy, Chisinau, Republic of Moldova
- 2Faculty of Medicine, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova
- 3Department of Endocrinology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova
Abstract
Objectives. Autoimmune hypothyroidism is associated with disturbances in lipid metabolism. This study assessed lipid profiles and cardiovascular risk markers in patients with overt (OH) and subclinical hypothyroidism (SH) compared with healthy controls, and examined lipid changes during levothyroxine treatment.
Methods. This observational case–control study included 129 adults: 65 patients with autoimmune hypothyroidism (35 OH, 30 SH) and 64 controls. All patients had complete lipid, TSH, and fT4 measurements at baseline, 8 weeks, and 16 weeks. Lipid indices included LDL cholesterol (LDL-c), HDL cholesterol (HDL-c), non-HDL cholesterol (non-HDL-c), and the total cholesterol/HDL-c ratio. Between-group comparisons and paired longitudinal tests were performed; longitudinal p values were not adjusted for multiple comparisons.
Results. Baseline LDL-c was higher in patients than controls (3.96 ± 1.67 vs 3.39 ± 0.76 mmol/L; p = 0.015). Non-HDL-c was higher in OH than SH (5.31 ± 2.19 vs 3.64 ± 0.96 mmol/L), and the total cholesterol/HDL-c ratio was higher in patients than controls (4.16 ± 1.59 vs 3.42 ± 0.75; p = 0.001). At 16 weeks, mean LDL-c decreased from 3.96 ± 1.67 to 3.28 ± 1.00 mmol/L (p = 0.001), and non-HDL-c from 4.54 ± 1.92 to 3.68 ± 1.17 mmol/L (p < 0.001). HDL-c did not improve significantly. At week 16, TSH was within the reference interval in 42 of 65 patients (64.6%).
Conclusions. Overt autoimmune hypothyroidism was associated with a more atherogenic lipid profile than SH or euthyroid status. During levothyroxine treatment, LDL-c and non-HDL-c improved, particularly in OH, while HDL-c did not. These observational findings do not establish a causal treatment effect or a reduction in cardiovascular events.
Related
- Residual Symptoms and Quality of Life in Female Patients with Hypothyroidism and Cardiovascular Disease
- Cardiovascular risk factors in autoimmune thyroiditis: role of adiponectin, resistin, inflammation and auto-immunity - a cross-sectional study.
- Massive Pericardial Effusion as a Manifestation of Severe Autoimmune Hypothyroidism in an Adolescent With Down Syndrome: Importance of Early Recognition and Thyroid Hormone Replacement.
- Cardiovascular risk profile and treatment patterns in patients with type 2 diabetes in specialized cardiology outpatient care in Colombia : A retrospective cross-sectional study
- Elevated lipoprotein (a) and large apo(a) isoforms in Omani patients: a distinct cardiovascular risk profile
BibTeX
@article{vudu2026lipid,
title = {{LIPID PROFILE AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH AUTOIMMUNE HYPOTHYROIDISM}},
author = {Stela Vudu and Tishya Mukherjee and Larisa Zota and Lorina Vudu},
journal = {Arta Medica},
year = {2026},
month = oct,
doi = {10.5281/zenodo.23678641},
url = {https://doi.org/10.5281/zenodo.23678641},
note = {CC BY-SA},
}
RIS
TY - JOUR
TI - LIPID PROFILE AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH AUTOIMMUNE HYPOTHYROIDISM
AU - Stela Vudu
AU - Tishya Mukherjee
AU - Larisa Zota
AU - Lorina Vudu
PY - 2026
DA - 2026/10/27
JO - Arta Medica
DO - 10.5281/zenodo.23678641
UR - https://doi.org/10.5281/zenodo.23678641
AB - Objectives. Autoimmune hypothyroidism is associated with disturbances in lipid metabolism. This study assessed lipid profiles and cardiovascular risk markers in patients with overt (OH) and subclinical hypothyroidism (SH) compared with healthy controls, and examined lipid changes during levothyroxine treatment. Methods. This observational case–control study included 129 adults: 65 patients with autoimmune hypothyroidism (35 OH, 30 SH) and 64 controls. All patients had complete lipid, TSH, and fT4 measurements at baseline, 8 weeks, and 16 weeks. Lipid indices included LDL cholesterol (LDL-c), HDL cholesterol (HDL-c), non-HDL cholesterol (non-HDL-c), and the total cholesterol/HDL-c ratio. Between-group comparisons and paired longitudinal tests were performed; longitudinal p values were not adjusted for multiple comparisons. Results. Baseline LDL-c was higher in patients than controls (3.96 ± 1.67 vs 3.39 ± 0.76 mmol/L; p = 0.015). Non-HDL-c was higher in OH than SH (5.31 ± 2.19 vs 3.64 ± 0.96 mmol/L), and the total cholesterol/HDL-c ratio was higher in patients than controls (4.16 ± 1.59 vs 3.42 ± 0.75; p = 0.001). At 16 weeks, mean LDL-c decreased from 3.96 ± 1.67 to 3.28 ± 1.00 mmol/L (p = 0.001), and non-HDL-c from 4.54 ± 1.92 to 3.68 ± 1.17 mmol/L (p < 0.001). HDL-c did not improve significantly. At week 16, TSH was within the reference interval in 42 of 65 patients (64.6%). Conclusions. Overt autoimmune hypothyroidism was associated with a more atherogenic lipid profile than SH or euthyroid status. During levothyroxine treatment, LDL-c and non-HDL-c improved, particularly in OH, while HDL-c did not. These observational findings do not establish a causal treatment effect or a reduction in cardiovascular events.
SN - 1810-1852
SN - 1810-1879
ER -